AVITA Medical (ASX:AVH) - CEO, Mike Perry
CEO, Mike Perry
Source: AVITA Medical
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Avita Medical (AVH) is included in the Russell 3000 Index as part of an annual reconstitution
  • The Russell Indexes’ reconstitution process captures the 4,000 largest US stocks every year and ranks them by total market capitalisation
  • Avita Medical’s CFO, Michael Holder, says the company looks forward to capitalising on this opportunity to broaden its stockholder base
  • Avita Medical is up 0.56 per cent, trading at $5.37 at 10:30 am AEST

Avita Medical (AVH) has been added to the Russell 3000 Index as part of an annual reconstitution.

Avita is a regenerative medicine company with a technology platform that addresses currently unmet medical needs in burns, chronic wounds, and aesthetics indications. The company’s patented technology offers innovative treatment solutions derived from the regenerative properties of a patient’s own skin.

The annual Russell indexes reconstitution process captures the 4,000 largest US stocks every year and ranks them by total market capitalisation.  

Russell indexes are used by investment managers and institutional investors for index funds and as a benchmark for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes.

Membership is primarily identified by objective, market-capitalisation rankings and style attributes, with each membership lasting one year.

Avita Medical’s membership in the Russell 3000 Index will result in automatic inclusion in the small-cap Russell 2000 Index, as well as in growth and value style indexes.

“We are excited to have been included in the Russell 3000 Index as part of the annual reconstitution,” Chief Financial Officer of Avita Medical, Michael Holder said.

“We look forward to capitalising on this opportunity to broaden our stockholder base.”

Avita Medical was up 0.56 per cent, trading at $5.37 at 10:30 am AEST.

AVH by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…